Compare LILA & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LILA | OGN |
|---|---|---|
| Founded | 2017 | 1923 |
| Country | Bermuda | United States |
| Employees | 10000 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | LILA | OGN |
|---|---|---|
| Price | $7.55 | $13.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $13.00 | $11.40 |
| AVG Volume (30 Days) | 222.0K | ★ 15.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.45 |
| Revenue Next Year | $7.23 | $1.67 |
| P/E Ratio | ★ N/A | $24.26 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.81 | $5.69 |
| 52 Week High | $9.04 | $13.44 |
| Indicator | LILA | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.15 | 77.58 |
| Support Level | $7.37 | $8.59 |
| Resistance Level | $8.24 | N/A |
| Average True Range (ATR) | 0.37 | 0.32 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 31.85 | 97.87 |
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.